celecoxib has been researched along with Scleroderma, Systemic in 2 studies
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sawamura, S | 1 |
| Kajihara, I | 1 |
| Ihn, H | 1 |
| Hachulla, E | 1 |
2 other studies available for celecoxib and Scleroderma, Systemic
| Article | Year |
|---|---|
A case of scleroderma associated with interstitial neutrophilic granulomatous reaction.
Topics: Administration, Oral; Adult; Biopsy, Needle; Celecoxib; Dermatitis; Female; Granuloma; Humans; Immun | 2019 |
[64th Congress of the American College of Rheumatology, Philadelphia, October 28-November 2, 2000].
Topics: Amyloidosis; Antiphospholipid Syndrome; Behcet Syndrome; Celecoxib; Cyclooxygenase Inhibitors; Giant | 2001 |